Paul A. Alappat, M.D.
Exemplar Research, Inc.
1325 Locust Avenue
Fairmont, WV 26554

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

AFFILIATIONS

Exemplar Research, Inc.
1526 Mileground Road
Morgantown, WV 26505

EDUCATION:

1985 Medical Doctor and Cardiologist
MBBS Kamatak Medical College, India

CERTIFICATION:

Board Certified in Cardiology
GCP Training: CITI
CPR Certified
ACLS Certified

LICENSURE:

1999 West Virginia Medical License # 19907

PROFESSIONAL EXPERIENCE:

Principal Investigator, 2010 – Present
Exemplar Research, Inc., Fairmont, WV

Physician, 1999 - Present
Consultant Associates, Fairmont, WV

Attending Physician, 1999 - Present
Fairmont Regional Medical Center (Formerly Fairmont General Hospital), Fairmont, WV

PROFESSIONAL EXPERIENCE (*continued*):

Attending Physician, 1999 - 2009
Monongalia General Hospital, Morgantown, WV

Clinical Instructor, 1996 - 1997
New York Hospital, Cornell Medical Center, New York, NY

Physician, 1994 - 1997
Private Practice, Long Island, NY

Fellowship Cardiology, 1994 - 1997
New York Hospital, Cornell Medical Center, New York, NY

Chief Medical Instructor, 1993 - 1994
New York Methodist Hospital, Brooklyn, NY

Attending Physician, 1992 - 1993
St. Mary's Hospital, Brooklyn, NY

INVESTIGATOR EXPERIENCE:

Angina • Diabetes Mellitus II •Acute Coronary Syndrome
Congestive Heart Failure • Hyperlipidemia • Hypertriglyceridemia

CLINICAL TRIAL EXPERIENCE:

A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with XXX in Type 2 Diabetic patients after an Acute Coronary Syndrome

A Phase III study designed as a double blind, randomized, multi-nation, multi-center, placebo controlled clinical research, which aims to evaluate the safety and efficacy of XXX in patients with chronic stable angina pectoris

A Phase III, double-blind, randomized placebo-controlled study to evaluate the effects of XXX on cardiovascular risk in a genetically defined population with a recent Acute Coronary Syndrome

A Phase III multi-center, double-blind, randomized, placebo-controlled, parallel group evaluation of the efficacy safety and tolerability of XXX in reducing the occurrence of major cardiovascular events in high risk subjects

A Phase III multi-center, double-blind, randomized, placebo-controlled, parallel group evaluation of the efficacy safety and tolerability of XXX in reducing the occurrence of major cardiovascular events in high risk subjects

CLINICAL TRIAL EXPERIENCE (*continued*):

Observational registry of treatment patterns in US Heart Failure Patients with reduced ejection fraction.